Head to head
CJC-1295 / Ipamorelin against CJC-1295
The blend against one of its components. No published study has tested CJC-1295 with ipamorelin in humans or in animals, so the blend's evidence is the sum of two separate single agent records, and the two components have half-lives that differ by roughly a hundredfold.
Column A
CJC-1295 / IpamorelinCJC-1295 and Ipamorelin blend (GHRH analogue plus ghrelin mimetic)
The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both.
Column B
CJC-1295CJC-1295 (GHRH analogue)
A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.
Side by side, on the facts we can check
| Attribute | CJC-1295 / Ipamorelin | CJC-1295 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Not approved. Neither component is an approved drug, and the combination has never been submitted or studied. | Not FDA-approved |
| Half-life | Not one number. The two components clear on completely different timescales, one within a few hours and the other over about a week. | ~6-8 days (DAC version) |
| Molecular weight | Mixture; CJC-1295 with DAC about 3,647.2 Da, ipamorelin 711.85 Da | 3,647.2 Da |
| Mechanism | Two receptors on the same pituitary cell. CJC-1295 activates the GHRH receptor, raising the amplitude of growth hormone pulses; albumin binding through the Drug Affinity Complex extends that signal for days in the DAC version. Ipamorelin activates the growth hormone secretagogue receptor GHS-R1a, the ghrelin receptor, which both releases growth hormone and suppresses somatostatin tone. Combining a GHRH agonist with a GHS-R agonist produces a larger pulse than either alone in human testing, though that testing used GHRH itself with GHRP-6, not this pair. | Activates the GHRH receptor on the pituitary to increase growth hormone secretion; albumin binding prolongs its activity. |
| Human studies cited | 3 | 2 |
| Legal status, US | Not approved; research use only | Not approved; research use only |
Frequently asked questions
What is the difference between CJC-1295 / Ipamorelin and CJC-1295?
CJC-1295 / Ipamorelin: The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both. CJC-1295: A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.
Which has stronger research evidence, CJC-1295 / Ipamorelin or CJC-1295?
This database does not grade compounds. It counts what was run in people: 3 of the 5 studies cited on the CJC-1295 / Ipamorelin profile were human work, against 2 of 2 for CJC-1295. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are CJC-1295 / Ipamorelin and CJC-1295 FDA-approved?
CJC-1295 / Ipamorelin: Not approved. Neither component is an approved drug, and the combination has never been submitted or studied.. CJC-1295: Not FDA-approved.
Related posts
Blog articles that cover CJC-1295 / Ipamorelin or CJC-1295, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.